Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics (KROS)
NASDAQ:KROS
Keros Therapeutics (KROS) Stock Price & Analysis
185 Followers
KROS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$27.02 - $73.00
Previous Close$54
Volume248.26K
Average Volume (3M)341.39K
Market Cap
$1.95B
Enterprise Value$1.67B
Total Cash (Recent Filing)$287.90M
Total Debt (Recent Filing)$14.31M
Price to Earnings (P/E)-10.5
Beta1.03
Next Earnings
Aug 01, 2024EPS Estimate
-$1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.14
Shares Outstanding36,083,886
10 Day Avg. Volume308,298
30 Day Avg. Volume341,394
Standard Deviation0.21
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)5.89
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-19.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue209.37K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-11.94
Forecast
1Y Price Target
$89.29Price Target Upside69.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Keros Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressKROS demonstrates a commitment to advancing their TGF-β pipeline with reaffirmed timelines for clinical programs, enhancing investor confidence in their study execution.
Financial StabilityKROS' robust financial position, with a cash runway extending into 2027, mitigates near-term liquidity risks and supports the company's ongoing research and development efforts.
Regulatory EngagementProgress in regulatory discussions is evidenced by KROS' engagement with the FDA on the Phase 3 trial design of KER-050 for myelodysplastic syndromes, potentially accelerating the path to market approval.
Bears Say
Drug EfficacySubgroup analyses suggest limited effect of Winrevair in patients with connective tissue disease, a significant portion of the PAH patient population.
Drug SafetyThe label includes warnings for Winrevair related to erythrocytosis, hemoglobin increases, and severe thrombocytopenia, requiring monitoring.
Regulatory ConcernsSotatercept's dose-dependent effects on hemoglobin and vascular adverse events could necessitate a REMS, highlighting potential safety risks.
---
Ownership Overview
30.18% Insiders
22.98% Mutual Funds
15.97% Other Institutional Investors
30.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KROS FAQ
What was Keros Therapeutics’s price range in the past 12 months?
Keros Therapeutics lowest stock price was $27.02 and its highest was $73.00 in the past 12 months.
What is Keros Therapeutics’s market cap?
Currently, no data Available
When is Keros Therapeutics’s upcoming earnings report date?
Keros Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 78 days.
How were Keros Therapeutics’s earnings last quarter?
Keros Therapeutics released its earnings results on May 08, 2024. The company reported -$1.21 earnings per share for the quarter, beating the consensus estimate of -$1.333 by $0.123.
Is Keros Therapeutics overvalued?
According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued.
Does Keros Therapeutics pay dividends?
Keros Therapeutics does not currently pay dividends.
What is Keros Therapeutics’s EPS estimate?
Keros Therapeutics’s EPS estimate is -$1.26.
How many shares outstanding does Keros Therapeutics have?
Keros Therapeutics has 36,083,885 shares outstanding.
What happened to Keros Therapeutics’s price movement after its last earnings report?
Keros Therapeutics reported an EPS of -$1.21 in its last earnings report, beating expectations of -$1.333. Following the earnings report the stock price went down -0.75%.
Which hedge fund is a major shareholder of Keros Therapeutics?
Among the largest hedge funds holding Keros Therapeutics’s share is Woodline Partners LP. It holds Keros Therapeutics’s shares valued at 23M.
---
Keros Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.29 (69.11% Upside)
$89.29 (69.11% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 85.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.10%
12-Months-Change
Fundamentals
Return on Equity
-39.63%
Trailing 12-Months
Asset Growth
26.37%
Trailing 12-Months
Company Description
Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
---
KROS Stock 12 Month Forecast
Average Price Target
$89.29
▲(69.11% Upside)
Technical Analysis
Best Analysts Covering KROS
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+19.32%
reiterated a buy rating 7 days ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +19.32% per trade.
---